Who Unicef JRF en

Annual Report on Immunization Performance for the Period
January-December 2016 from Ministry of Health

<<Country Name>>
to WHO/UNICEF (WHO/UNICEF Joint Reporting Form on Immunization)
If a question is not relevant, enter "NR" (not relevant).

If no data are available, enter "ND" (no data).
If the number of cases is zero, enter 0.
cells with blue background provide a drop down list to choose your entry
Some parts of this form have instructions. You can read the
instructions by clicking on the blue, underlined links.
You can perform standard Excel mathematical operations (such as addition or
multiplication) in cells.
Data reported in previous years are available from the following websites:
(1) WHO (http://www.who.int/immunization/monitoring_surveillance/data/en/)
(2) UNICEF (http://www.data.unicef.org/child-health/immunization)
Country: Date report submitted: 2017
#N/A
(instructions)
Name of person in Ministry of Health
0010
responsible for completing this form
0020 Position/title
0030 Email address
Name of UNICEF contact (Name of the UNICEF contact

0040
in the UNICEF Office if exists)
0050 Email address of UNICEF contact
Name of WHO contact (Name of the WHO contact in

0060
the WHO Office if exists)
0070 Email address of WHO contact
Total number of districts in the country (instructions)

0080
during 2016
#VALUE!
WHO/UNICEF JRF data for 2016000000

Section Cover Page, pg. 1
360754162.xls
1. Reported Cases of Selected Vaccine Preventable Diseases (VPDs)
Reported cases for the year 2016
Laboratory Investigation C. Confirmed Cases

Total confirmed cases; include all
cases confirmed by laboratory
A.
testing or epi linkage, plus those
Disease Number of suspected cases B.
clinical cases that were reported
tested Number of cases positive
without a laboratory specimen or
epi linkage
#VALUE! #VALUE! #VALUE!
1010 Diphtheria
1020 Measles
1030 Neonatal tetanus (NT)
1040 Total tetanus (all tetanus including NT)
1050 Pertussis
1060 Yellow fever #VALUE!
1070 Japanese encephalitis #VALUE!
1080 Mumps
1090 Rubella
1100 Congenital rubella syndrome
#VALUE!

Section 1. Reported Cases, pg. 2
360754162.xls
2A. Immunization Schedule for 2016
Describe the 2016 national immunization schedule for routine services in the following table. Include all doses administered to young children, adolescents, and adults on a routine basis.
Each row describes a vaccine or combination vaccine. Include vitamin A if it is delivered through routine immunization services. Also include information about the use of auto-disable
(AD) syringes.
If there are plans to introduce a vaccine, supplement, or syringe, enter the month and year that the introduction is planned in columns G-H.
If the immunization schedule includes other vaccines that are not listed, add them at the bottom of the table.
#VALUE!
Recommended age of administration I.

(B=birth; D=days; W=weeks; M=months; G-H. Geographic J.
Y=years) Planned introduction area Specific target group
Vaccine, Supplement,
or Injection Equipment #VALUE!
A. B. C. D. E. F. #VALUE! #VALUE!
1st 2nd 3rd 4th 5th 6th Month Year
dose dose dose dose dose dose
2010 BCG Bacille Calmette-Gurin vaccine <pick one>

<pick cell
2020 DTP Diphtheria and tetanus toxoid with pertussis vaccine <pick one>
type>
Diphtheria and tetanus toxoid with pertussis and HepB <pick cell
2030 DTP-HepB <pick one>
vaccine type>
DTP-HepB- Diphtheria and tetanus toxoid with pertussis, HepB and IPV <pick cell
2040 <pick one>
IPV vaccine type>
DTP-Hib- Diphtheria and tetanus toxoid with pertussis, Hib and HepB <pick cell
2050 <pick one>
HepB vaccine type>
<pick cell
2060 DTP-Hib Diphtheria and tetanus toxoid with pertussis and Hib vaccine <pick one>
type>
Diphtheria and tetanus toxoid with pertussis, Hib and IPV <pick cell
2070 DTP-Hib-IPV <pick one>
vaccine type>
Diphtheria and tetanus toxoid with pertussis, Hib, hepatitis B <pick cell
2080 DTP-Hib-HepB-IPV <pick one>
and IPV vaccine type>
<pick cell
2090 DTP-IPV Diphtheria and tetanus toxoid with pertussis vaccine and IPV <pick one>
type>
Tetanus and diphtheria toxoid with inactivated polio vaccine, children's

2100 DT-IPV <pick one>
dose
2110 Dip Diphtheria vaccine, children's dose <pick one>
2120 DT Tetanus and diphtheria toxoid, children's dose <pick one>
2130 Td Tetanus and diphtheria toxoid for older children and adults <pick one>
Tetanus, diphtheria toxoid, acelular perussis for older children and

2140 TdaP <pick one>
adults
Tetanus, diphtheria toxoid, acellular pertussis with inactivated polio

2150 TdaP-IPV <pick one>
vaccine for older children and adults
Tetanus, diphtheria toxoid with inactivated polio vaccine for older

2160 Td-IPV <pick one>
children and adults
2170 TT Tetanus toxoid <pick one>

<pick cell
2180 P Pertussis vaccine <pick one>
type>
2190 Diphtheria Diphtheria vaccine for older children and adults <pick one>
2200 HepA_Adult Adult Hepatitis A vaccine <pick one>
2210 HepA_Pediatric Pediatric Hepatitis A vaccine <pick one>
2220 HepB_Adult Adult Hepatitis B vaccine <pick one>
2230 HepB_Pediatric Pediatric Hepatitis B vaccine <pick one>
2240 Hib Haemophilus influenza type b vaccine <pick one>
2250 OPV Oral polio vaccine <pick one>
2260 IPV Inactivated polio vaccine <pick one>
2270 Measles Measles vaccine <pick one>
2280 MM Measles and mumps vaccine <pick one>
2290 MR Measles and rubella vaccine <pick one>
2300 MMR Measles, mumps and rubella vaccine <pick one>
2310 MMRV Measles, mumps, rubella and varicella vaccine <pick one>
2320 Mumps Mumps vaccine <pick one>
2330 JE_LiveAtd Japanese encephalitis live attenuated vaccine <pick one>
2340 JE_Inactd Japanese encephalitis inactivated vaccine <pick one>
2350 JE_rec JE recombinant vaccine <pick one>
2360 Influenza_Adult Adult seasonal influenza vaccine <pick one>

Influenza_Pediatri
2370 Pediatrict seasonal influenza vaccine <pick one>
c
2380 MenC_conj Meningococcal C conjugate vaccine <pick one>
2390 Men AC Meningococcal AC <pick one>
2400 Men ACW Meningococcal ACW <pick one>

Men ACWY-
2410 Meningococcal ACWY-135 (conjugate vaccine) <pick one>
135_conj
Men ACWY-
2420 Meningococcal ACWY-135 (polysacccharide vaccine) <pick one>
135_ps
2430 Men A Meningococcal A conjugate vaccine <pick one>
No. of
2440 Pneumoco_ conj Pneumococcal conjugate vaccine valents: <pick one>
2450 Pneumo_ps Pneumococcal polysaccharide vaccine <pick one>
2460 Rubella Rubella vaccine <pick one>
2470 Typhoid Typhoid fever vaccine <pick one>
2480 Varicella Varicella vaccine <pick one>
2490 YF Yellow fever vaccine <pick one>

No. of
2500 Rotavirus Rotavirus vaccine valents: <pick one>
No. of
valents:
Include target age or
school class and specifiy if
2510 HPV Human papillomavirus vaccine <pick one> this applies to females
only, males as well and
any special groups
2520 Cholera Cholera vaccine <pick one>
2530 Vit A Vitamin A supplements <pick one>
USE THE LINES BELOW TO DESCRIBE OTHER VACCINES
2540 <pick one>
2550 <pick one>
2560 <pick one>
2570 <pick one>
2580 <pick one>
2590 <pick one>
2600 <pick one>
2610 <pick one>
2620 <pick one>

Section 2A. Schedule, pg. 3
360754162.xls
Home-based vaccination records (records reflecting immunization history/status and kept with vaccinee, or caregiver of vaccinee) Explanatory comments
Total number of home-based records for children (e.g., vaccination card, vaccination card+growth monitoring, or child health booklets) printed for use
2630 #VALUE!
during 2016
Total number of home-based records for women of child bearing age (WCBA) (e.g., vaccination cards for TT/Td or maternal health books) printed for
2640 #VALUE!
use during 2016
EPI/Ministry of Health (MoH) <pick one>
Which organization is responsible for financing the home-based records for children in your country?
(Note: If the private sector prints and distributes a separate home-based vaccination record from that Other government agency <pick one>
distributed by government (national or local), then indicate under 'Other' and include an explanatory
2650 comment.)
Development partner (specify under explanatory comments) <pick one>
#VALUE! Other (specify under explanatory comments) <pick one>
Is the printing of home-based vaccination records for children the responsibility of the national
EPI/Ministry of Health (MoH) <pick one>
programme (EPI or MOH)?
2660
#VALUE! Other (please specify under explanatory comments) <pick one>
2700 Comments
#VALUE!

Section 2A. Schedule, pg. 4
360754162.xls
2B. Vaccine price and procurement information
In 2015 Ministers of Health at the World Health Assembly (WHA) voted on Resolution 68.6 on the Global Vaccine Action Plan (GVAP) urging all member states "to provide, where possible and available, timely vaccine price data to WHO. Information collected is made available to benefit Member
States: to improve decision making on new vaccine introduction and budgeting as well as to enhance access to affordable prices.
In 2016, WHO decided to include vaccine pricing and procurement information in the WHO/UNICEF Joint Reporting Form in order to report back this information at subsequent World Health Assemblies, through the GVAP annual monitoring and as a way of increasing price transparently across WHO
member states.
Data collected in this spreadsheet and subsequent analyses will be made available through the Vaccine Product, Price and Procurement (V3P) website: www.who.int/immunization/v3p.
As some of the questions asked in this sheet require technical knowledge of vaccine procurement and pricing, it is adviced to request input by country procurement officers.
Please request this information by the relevant authority in the Ministry of Health that have access to this information.
Note: For countries procuring through the PAHO Revolving Fund, please skip pricing indicators in 2Bb, as this information is directly provided by the Revolving Fund to the V3P database.
2Ba. Procurement and sources of vaccines 2Bb. Vaccine pricing

Use columns A through I to record sources of vaccines and procurement information on all vaccines procured during the reporting period 1 January 31 December 2016. Use columns J to P to provide information about the price of vaccines procured during the reporting period 1 January 31
December 2016.
If several manufacturers or procurement mechanisms were used for the same vaccine, list them all.
Please make sure that all vaccines reported in sheet "2A.Schedule" are also reported here. Do not hesitate to provide details and clarifications in the "Comments" section.
If several manufacturers or procurement mechanisms were used for the same vaccine, list them all.
D:
M.
C. Number of doses F. K. L.
G. H. I. J. If yes, what
A. B. Presentation per primary E. Total number Currency Is goods tax N. O.
Authority responsible for Procurement Contract Vaccine price is the P.Comments
Contracting year Vaccine type (eg, vial, container Name of manufacturer of doses (e.g. EUR, (VAT) included Incoterm Source of funding
vaccine procurement mechanism length per dose percentage of
ampoule, etc) (e.g. 1, 10, 20-dose procured USD, etc.) in the price?
VAT?
etc.)
#VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
B_2010 <pick one> <pick one> <pick one> <pick one> <pick one> <pick one> <pick one> <pick one> <pick one> <pick one>

Section 2B.Procurement_pricing, pg. 5
360754162.xls
D:
M.
C. Number of doses F. K. L.
G. H. I. J. If yes, what
A. B. Presentation per primary E. Total number Currency Is goods tax N. O.
Authority responsible for Procurement Contract Vaccine price is the P.Comments
Contracting year Vaccine type (eg, vial, container Name of manufacturer of doses (e.g. EUR, (VAT) included Incoterm Source of funding
vaccine procurement mechanism length per dose percentage of
ampoule, etc) (e.g. 1, 10, 20-dose procured USD, etc.) in the price?
VAT?
etc.)
#VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
#VALUE!

Section 2B.Procurement_pricing, pg. 6
360754162.xls
School Based Immunization
Please complete this section if routine immunization doses are given to school-aged children using the school as a venue or delivery point. For the purpose
of this section, please consider as "routine" only those doses that are part of the national immunization schedule. Report only on the school-based
vaccinations that are implemented on a regular or annual basis for the same age group as part of the national immunization schedule. Do not report on
doses given during national immunization days (supplementary activities).
3000 Are any routine doses of vaccine given to children at school? <pick one>
If yes, please continue with questions 3010-3180; otherwise go to Sheet 4A.
3010 Vaccine procurement <pick one>
3020 Which activities is the EPI Program responsible for (and not the Vaccinators <pick one>
3030 school staff per se): Supervision <pick one>
3040 Planning <pick one>
3050 Is this part of a comprehensive school health program that delivers other health interventions also? <pick one>
Routine Immunization given at school (please complete one row for each grade level (or age) and vaccine)
#VALUE!
G.
H.
D. E. F. Other
A. B. C. Doses recorded
Geographic Number in Number of doses interventions
Vaccine Grade/ Level Age Group Sex on home-based
Area target group administered at school given with the
record
vaccine
#VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
3060 <pick one> <pick one> <pick one>
3180 Comments
#VALUE!

Section 3.School_Imm_delivery, pg. 7
360754162.xls
4. Immunization and Vitamin A Coverage
4A. National Administrative Coverage for the Year 2016
Administrative coverage
#VALUE!
A. B. C. D.
Vaccine/Supplement
Description of the denominator Number in target Percent coverage
Please complete separately for each vaccine, used in coverage calculation group Number of doses (=C/B*100)
even if they are given in combination (e.g., if (denominator) administered through
Pentavalent vaccine DTP-HepB-Hib is used, fill in routine services
the data for DTP3, HepB3 and Hib3 separately) (numerator)
#VALUE! #VALUE!
4010 BCG live births
HepB, birth dose (given within 24

4020 #VALUE! live births
hours of birth)
HepB, birth dose total (including

4030 those given within and after 24 #VALUE! live births
hours of birth)
4040 DTP1 surviving infants
4050 DTP3 surviving infants
<Please enter target

4060 DTP4, 1st booster
population>
1st dose of inactivated polio containing vaccine
4070 surviving infants
(IPV1)
4080 Polio3 (OPV or IPV) #VALUE! surviving infants
4090 HepB3 #VALUE! surviving infants
4100 Hib3 surviving infants
4110 Pneumococcal conjugate vaccine 1st dose surviving infants
4120 Pneumococcal conjugate vaccine 2nd dose surviving infants
<Please enter target

4130 Pneumococcal conjugate vaccine 3rd dose
population>
4140 Rotavirus 1st dose surviving infants
Rotavirus last dose

(2nd or 3rd depending on schedule)
Measles-containing vaccine, 1st
dose (MCV1)
Rubella-containing vaccine, 1st <Please enter target
4170 #VALUE!
dose (RCV1) population>
Measles-containing vaccine, 2nd <Please enter target
4180
dose (MCV2) population>
4190 Yellow fever vaccine surviving infants
4200 Meningococcal A conjugate vaccine surviving infants
4210 Vitamin A, 1st dose less than 59 months
4220 Japanese encephalitis vaccine <Please enter target

population>
pregnant
4230 Tetanus toxoid-containing vaccine (TT2+/Td2+) #VALUE!
women
Protection at birth (PAB) against
4240 #VALUE! live births
neonatal tetanus
Does your recording system allow for capture of data, at the national level, on the number
of delayed or late doses administered (i.e., vaccine doses administered to children older
4250 #VALUE! < pick one > <comment>
than the recommended age for receipt of vaccine dose in the national immunization
schedule)?
If MCV1 is recommended in the routine schedule at

less than 12 months (e.g., 9-11 months) how many
4260 doses of MCV1 were administered at 12-23 months #VALUE! <comment>
If yes, please answer just one of the in 2016?
two proposed questions, as
appropriate for the national routine
schedule If MCV1 is recommended in the routine schedule at
4270 12 months or later, how many late or delayed MCV1 #VALUE! <comment>
doses were administered in 2016 (total number)?

Section 4A. Routine Coverage, pg. 8
360754162.xls
Accuracy of administrative coverage
#VALUE!
Describe any factors limiting the accuracy of the numerator:
4280
Explain how the denominators are obtained and which institution provided the official denominator for 2016.
(denominator = number in target group)
4290
Describe any factors limiting the accuracy of the denominator:
4300
Completeness of district level reporting

#VALUE!
4310 Total number of district reports expected at the national level from all districts across reporting periods in 2016 (e.g., # districts x 12 months)
4320 Total number of district reports actually received at the national level from all districts across reporting periods in 2016
HPV Vaccine Doses administered: 2016

#VALUE!
Females
Vaccine administered (age in A. B. C.

years) 1st dose 2d dose 3d dose*
4330 9
4340 10
4350 11
4360 12
4370 13
4380 14
4390 15+
4400 unknown age
* WHO recommends a 2-dose schedule for girls < 15 years of age (Position Paper
published in October 2014). If 2-dose schedule was used please leave Column C blank.
Accuracy of reported HPV Vaccine Doses

Describe any factors limiting the accuracy of the administered doses :
4410
#VALUE!

Section 4A. Routine Coverage, pg. 9
360754162.xls
4. Immunization and Vitamin A Coverage
4B. Coverage Surveys
Conducted in 2014-2016
4420 Year of most recent survey #VALUE! <pick one>
Full title of survey in the language of the

4430
original report
4440 Full title of survey in English
Please include a copy of all coverage survey reports, including surveys with
immunization modules, conducted from 2014 to 2016 with the submission of your JRF.
Make sure to include all surveys reporting on Vitamin A coverage, including nutrition
surveys.
Planned for 2017-2018
Is a coverage survey planned for the next

4450 <pick one>
24 months?
What type of survey is planned? (e.g.,

4460
MICS, DHS, EPI or CES)
#VALUE!

Section 4B. Coverage Surveys, pg. 10
360754162.xls
5. Official Country Estimates of Immunization Coverage
for the Year 2016
Please explain from what data your official estimates are derived. If the official estimates differ from the
administrative coverage, please explain the difference.
5000
#VALUE!
Please complete separately for each vaccine, even if they are given in combination (e.g., if Pentavalent vaccine DTP-HepB-Hib
is used, fill in the data for DTP3, HepB3 and Hib3 separately)
Official coverage estimates

Vaccine/Supplement
(percent coverage)
5010 BCG
5020 HepB, birth dose (given within 24 hours of birth)
HepB, birth dose total (including those given within and after 24 hours of
5030
birth)
5040 DTP1
5050 DTP3
5060 DTP4, 1st booster
5070 1st dose of inactivated polio containing vaccine (IPV1)
5080 Polio3
5090 HepB3
5100 Hib3
5110 Pneumococcal conjugate vaccine 1st dose
5120 Pneumococcal conjugate vaccine 2nd dose
5130 Pneumococcal conjugate vaccine 3rd dose
5140 Rotavirus 1st dose

Rotavirus last dose
5150
(2nd or 3rd depending on schedule)
5160 Measles-containing vaccine, 1st dose (MCV1)
5170 Rubella-containing vaccine 1st dose (RCV1)
5180 Measles-containing vaccine, 2nd dose (MCV2)
5190 Yellow fever vaccine
5200 Meningococcal A conjugate vaccine
5210 Vitamin A, 1st dose
5220 Japanese encephalitis vaccine
5230 Tetanus toxoid-containing vaccine (TT2+/Td2+) for pregnant women
Does the above official coverage estimates for vaccines

5240 delivered to newborns or infants include vaccines delivered by #VALUE! <Pick one>
the private providers, regardless of source of procurement?
5250 If partially, specify what percentage
Do the above official coverage estimates for vaccines delivered to newborns or

infants include vaccines delivered by Social Security, Non-government
5260 <Pick one>
organizations (NGOs), armed forces, and missionary/faith-based regardless of
source of procurement?
5270 If partially, specify what percentage
#VALUE!

Section 5. Official Estimates, pg. 11
360754162.xls
6. Immunization System Indicators
Planning and management

Explanatory
System indicator Response
comments
#VALUE!
Does the country have a multi-year plan (MYP) for
6010 <pick one>
immunization?
6020 If yes, what years does the MYP cover?
6030 Did the country have an annual workplan for immunization activities in 2016? <pick one>
Number of districts with updated routine immunization micro-plans to raise

6040
immunization coverage
#VALUE!
Does the immunization programme have a comprehensive
6050 <pick one>
multi-year immunization supply chain improvement plan?
National Immunization Advisory Group (NITAG)

Explanatory
System indicator Response
comments
Did your country have a standing technical advisory group

on immunization in 2016?
6060 (Do not report on Inter Agency-Country Committee (ICC)) #VALUE! <pick one>
If yes, please continue with questions 6070-6210;
otherwise go to question 6220
Does the advisory group have formal written terms of

6070 #VALUE! <pick one>
reference?
Are there legislative or administrative basis for the advisory

group?
6090 pediatrics <pick one>

Are the following areas of expertise
represented in the group as core
6100 public health <pick one>
membership?
6110 infectious diseases <pick one>
6120 epidemiology <pick one>
6130 #VALUE! immunology <pick one>
other: please specify under

6140 <pick one>
explanatory comments
6150 How many times did the advisory group meet in 2016? #VALUE!
Were the agenda and background documents distributed

(at least 1 week) prior to meetings in 2016?
Are members of the advisory group required to disclose

conflict of interest?
Does the advisory group have a website or webpage? If

6180 yes, please provide the address under explanatory #VALUE! <pick one>
comments.
6190 Did your country conduct an assessment of its existing NITAG in 2016? <pick one>
the NITAG Evaluation tool

developed by WHO and AMP's
Health Policy and Institutional
Development (HPID) centre (WHO
6200 If yes, which tool was used? <pick one>
Collaborating Centre for evidence-
informed immunization policy-
making)
another tool: please indicate which

6210 #VALUE! one in the explanatory comments <pick one>
cell

Section 6. Indicators, pg. 12
360754162.xls
District coverage reported for routine immunization services in 2016
#VALUE!
A. B. C. D. E. F.
number of
DTP3 Coverage is Coverage is Coverage is Coverage is Coverage is
districts not
<50% 5079% 8089% 90%-94% >95%
reporting
Number of districts with DTP3 coverage in
6220
each range
Number of surviving infants in these
6230
districts
Number of districts reporting DTP drop-
6240
out rates greater than 10%
Measles <50% 5079% 8089% 90%-94% 95%
Number of districts with measles (MCV1)

6250
coverage in each range
Number of surviving infants in these
6260
districts
Number of districts with measles (MCV2)
6270
coverage in each range
Number of children in the target
6280
population in these districts
PAB (protection at birth) <50% 5079% 8089% 90%-94% 95%

Number of districts with PAB coverage in
6290
each range
6300 Number of live births in these districts
6310 Number of districts reporting DTP drop-out rates greater than 10% #VALUE!
Vaccine supply and commodities for routine services

Vaccine/Supplies National store District stores
A. B. C. D. E. F:
Was there a If yes, specify Did a vaccine If yes, was the If yes, were Main Cause of
stock-out (no duration of stock-out district level vaccination the national
remaining stock-out in occur at stockout linked to a services stockout
doses for any months district level national level interrupted
Please complete separately for each
period of during 2016? stockout of because of the
vaccine, even if they were given in
time) at the vaccine? lack of each of
combination
national level the listed
(e.g., DTP and HepB)
during 2016? vaccines?
#VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
6320 BCG <pick one> <pick one> <pick one> <pick one> <pick one>
6330 DTP-containing vaccines <pick one> <pick one> <pick one> <pick one> <pick one>
6340 Hepatitis B-containing vaccines <pick one> <pick one> <pick one> <pick one> <pick one>
6350 Hib-containing vaccines <pick one> <pick one> <pick one> <pick one> <pick one>
6360 Pneumococcal conjugate vaccine <pick one> <pick one> <pick one> <pick one> <pick one>
6370 Rotavirus <pick one> <pick one> <pick one> <pick one> <pick one>
6380 Polio - OPV <pick one> <pick one> <pick one> <pick one> <pick one>
6390 Polio - IPV <pick one> <pick one> <pick one> <pick one> <pick one>
6400 Measles-containing vaccines <pick one> <pick one> <pick one> <pick one> <pick one>
6410 Yellow fever <pick one> <pick one> <pick one> <pick one> <pick one>
6420 Meningococcal A conjugate vaccine <pick one> <pick one> <pick one> <pick one> <pick one>
6430 Human Papillomvirus Vaccine (HPV) <pick one> <pick one> <pick one> <pick one> <pick one>
6440 Tetanus toxoid <pick one> <pick one> <pick one> <pick one> <pick one>

360754162.xls
Was there a stock-out of home-based vaccination records for children (no remaining home
based records for any period of time) at the national level during 2016?
6460 Is an electronic vaccine stock management system in place at district levels and below? #VALUE! <pick one>
What percentage (%) of the cold chain equipment (at all sub-national levels of the system) is
6470 #VALUE!
equipped with electronic continuous temperature monitoring systems?
6480 Does the immunization programme have a dedicated immunization supply chain manager at #VALUE! <pick one>
national level?
6490 Are vaccines at national level stored and/or transported together with other health #VALUE! <pick one>
commodities?
Is there a formal policy recommending against the storage and/or transportation of other
temperature sensitive pharmaceuticals with vaccines?
Is there a practice of storing and/or transporting other temperature sensitive pharmaceuticals in

the vaccine cold chain at any level of the vaccine supply chain?
Safety data
6520 In 2016 was a policy being implemented for immunization injection safety? <pick one>
6530 Does your country have a vaccine adverse events review committee? #VALUE! <pick one>
6540 Is there a national system to monitor adverse events following immunization? #VALUE! <pick one>
If yes, how many total adverse events, including suspected or confirmed, were reported to the national level in
6550 2016? (Please include ALL cases that are documented from ALL sources, i.e. cases that have at least a reporting
form and/ or are linelisted from routine, campaigns, immunization weeks, school health programs etc)
6560 Of the total adverse events reported (in the row above), how many were "serious"? #VALUE!
6570 The source of data for the total number of adverse events (row 6560) is: #VALUE! <pick one>
6580 In 2016 was there a national policy for waste from immunization activities? <pick one>
Incineration <pick one>
What was the recommended practice for disposal of Open burning <pick one>
6590 immunization waste in 2016? Pick "yes" for all that apply. #VALUE!
Burial <pick one>
Other <pick one>
Financing data
Are there line items in the national government budget specifically for the purchase of vaccines
6600 used in routine immunizations #VALUE! <pick one>
What is the government expenditure on vaccines used in routine immunization (Please remain
consistent when you are reporting, and keep all units either in local currency or US$)
What is the total expenditure (from all sources) on vaccines used in routine immunization? All
sources refers to government, domestic private partners, and international partner agencies,
other. (Please remain consistent when you are reporting, and keep all units either in local
currency or US$)
Calculate the percentage of total expenditure on vaccines financed by government funds

6630 #VALUE!
using indicators 6610 and 6620. (6610/6620)x 100
What is the government expenditure on routine immunization, including vaccines? (Please

remain consistent when you are reporting, and keep all units either in local currency or US$).
NB: This indicator is used to monitor country progress toward Global Vaccine Action Plan (GVAP)
commitments and reported on an annual basis to the World Health Assembly
What is the total expenditure (from all sources) on routine immunization, including vaccines?
6650 (Please remain consistent when you are reporting, and keep all units either in local currency or #VALUE! <pick one>
US$).
Calculate the percentage of total expenditure on routine immunization financed by

6660 #VALUE!
government funds using indicators 6640 and 6650. (6640/6650) x 100
6670 Comments
All the terms used in these instructions are defined in the glossary included and further explained in the
Guidance Note posted on
http://www.who.int/immunization/programmes_systems/financing/en/

360754162.xls
Seasonal Influenza data
Does the country have a formal national (governmental) seasonal influenza vaccination policy? (If a non-governmental
6680 organization or society recommends influenza vaccine, but there is no formal governmental recommendation, please <pick one>
choose no)
Children ( (if yes, specify age range in

<pick one>
comment field)
Older persons (if yes, specify age

<pick one>
range in comment field)
Chronic illness (paediatric) <pick one>
Chronic illness (adult) <pick one>
Pregnant women <pick one>

Which risk groups if any, are recommended for seasonal influenza vaccination
6690
by the national (governmental) policy?
Health care workers <pick one>
Haj or other travellers <pick one>
Any other risk group (if yes, please

<pick one>
specify in the comment field)
All persons >6 months are

<pick one>
recommended to receive vaccine
No groups are specified for influenza

<pick one>
vaccine receipt
6700 How many doses of seasonal influenza vaccine were distributed in 2016?
6710 What seasonal influenza vaccine formulation was used in 2016? <pick one>
6720 What was the percentage (%) of elderly persons immunized against influenza in 2016?
6730 What was the percentage (%) of persons with underlying disease immunized against influenza in 2016?
Vaccine Hesitancy
#VALUE!
Please fill in all questions. Please provide the reasons for vaccine hesitancy even if it is based on your opinion and no underlying research has been conducted. Please
indicate whether or not an assessment has been done. If available, kindly provide the link or reference to the publication/report or attach to this report
6740 What are the top three reasons for hesitancy to accept vaccines according to the national schedule in 2016?
Is this response based or supported by some type of assessment, or is it an opinion based on your knowledge and
6750 <pick one>
expertise?
Has there been some assessment (or measurement) of vaccine hesitancy at national or subnational level in the past
6760 <pick one>
(<5 years)?
6770 If yes, please specify the type and the year and provide assessment title(s) and reference(s) to any publication/report
Vaccine Demand
Implementing activities (e.g. training) to prepare for, prevent, manage or
6780 In 2016, what did the countrys communicate about adverse events following immunization (AEFIs) or other <pick one>
immunization program (at the national or vaccine related events (e.g. address rumours)?"
lower levels) do to promote or sustain
public (individuals and communities) Partnering with local leadership and/or CSOs to enhance the quality and
6790 <pick one>
demand for vaccines and vaccination accountability of services including seeking out community concerns
services (directly or indirectly; alone or in
coordination with/through partner
6800 agencies and/or CSOs)? Training health workers on interpersonal communication skills <pick one>
Did the countrys immunization program

6810
(at the national or lower levels)
implement any other activities (directly or
indirectly; alone or in coordination
6820 with/through partner agencies and/or
CSOs), do anything else to stimulate and
sustain public demand for vaccines and
6830 vaccination services? Please describe up
to three activities.
#VALUE!

360754162.xls
8. Supplementary Activities
Please record any additional immunization and nutritional interventions, including Vitamin A and iron supplementation, deworming, and the distribution of insecticide treated bednets.
Conducted during 2016
#VALUE!
A. B. C. D. E. F. G. Number of persons vaccinated for
Round and type Date Geographic Target Estimated Total number of Coverage tetanus
of activity Area population number in persons (%) (columns must add up to
Vaccine/ Total Number of Persons Vaccinated)
target vaccinated or
supplement
#VALUE! (instructions)
#VALUE! population supplemented #VALUE! H. I. J. K.
TT1 TT2 TT3 TT4 or
more
8010 <pick one>
8020 <pick one>
8030 <pick one>
8040 <pick one>
8050 <pick one>
8060 <pick one>
8070 <pick one>
8080 <pick one>
8090 <pick one>
8100 <pick one>
8110 <pick one>
8120 <pick one>
8130 <pick one>
8140 <pick one>
8150 <pick one>
8160 <pick one>
8170 <pick one>
8180 <pick one>
8190 <pick one>
8200 <pick one>
Planned for 2017-2018
#VALUE!
C. D. E.
A. B. Geographic Target Estimated
Round and type Date Area population number in target
Vaccine/ of activity population
supplement
(instructions)
#VALUE! Month Year #VALUE!
#VALUE!

Section 8. Supplementary, pg. 16
360754162.xls
Thank you for filling in the form.
If you have any comments please use this sheet to add them.

Section 9_General_comments, pg. 17
360754162.xls
Return
Item(s) Instructions
to item
Cover page
List the name of the person responsible for submitting the completed form. Since multiple
departments in the Ministry of Health may have relevant data, this person should liaise
0010 with other departments to ensure that the form contains the most accurate and complete #VALUE!
data possible. For example, information on Vitamin A may come from the nutrition
department.
0080 A district is defined as the third administrative level (nation is the first, province is the second). #VALUE!
1. Reported cases of selected VPDs
10101100 In column A enter the total number of suspected cases for which specimens were
#VALUE!
(A) collected and tested in a laboratory, regardless of final results of testing
Column B should give the total number of cases for which specimens with positive results
10101100 (B) #VALUE!
after testing in a laboratory
Column C should contain the total confirmed cases; include all cases confirmed by lab
testing or epi linkage, plus those clinical cases that were reported without a lab specimen
or epi linkage. Measles clinical cases are defined as those cases with fever and
maculopapular (non-vesicular) rash and having cough, coryza or conjunctivitis, for which
no adequate clinical specimen was taken and which has not been linked epidemiologically
1010-1100
to a laboratory-confirmed case of measles or another laboratory-confirmed communicable #VALUE!
(C)
disease. Rubella clinical cases are defined as those cases with maculopapular (non-
vesicular) rash and fever (if measured) and one of arthritis/arthralgia or
lymphadenopathy, for which no adequate clinical specimen was taken and which has not
been linked epidemiologically to a laboratory-confirmed case of rubella or another
laboratory-confirmed communicable disease. In a measles/rubella surveillance system
with a suspect case definition of only fever and rash, cases not meeting the clinical case
definition should not be classified as clinically compatible cases.
1060 (C) FOR YELLOW FEVER : only include cases tested and confirmed by a laboratory #VALUE!
1070 (C) FOR JAPANESE ENCEPHALITIS: do not report clinically confirmed cases #VALUE!
2. Home-based vaccination records
Report the number of home-based records printed for recording vaccinations received by children /
infants use during 2016. A home-based vaccination record is a document (more often physical than
electronic) issued to an individual person by an official authority such as a national, provincial or
district health department on which an individuals history of vaccinations received from all health
2630 care providers is recorded. #VALUE!
Use the explanatory comment field to briefly describe the source of the number of home-based records
(e.g., printing invoice or order form, estimate based on births plus overage, etc).
If home-based records for children are printed at subnational levels rather than national levels and no
data is available, then report ND for no data and provide an explanatory comment.
If home-based records are printed for distribution in more than one year, then report the expected
number distributed during 2016.
If the private sector immunization service delivery utilizes a home-based record that is different from
that utilized by public/government provided immunization services, then make a note in the explanatory
comment including whether the number of records printed includes an estimate of the private sector
printed home-based records.
If home-based records for children are not used in the country, report NR for not relevant.
Report the number of home-based records printed for recording vaccinations received by
women of child bearing age. These may include vaccination cards for TT/Td or maternal
health books.
Use the explanatory comment field to briefly describe the source of the number of home-
based records (e.g., printing invoice or order form, estimate based on births plus overage,
etc).
If home-based records for WCBA are printed at subnational levels rather than national
2640 levels and no data is available, then report ND for no data and provide an explanatory #VALUE!
comment.
If home-based records for WCBA are printed for distribution in more than one year, then
report the expected number distributed during 2016.
If the private sector immunization service delivery utilizes a home-based record that is
different from that utilized by public/government provided immunization services, then
make a note in the explanatory comment including whether the number of records printed
includes an estimate of the private sector printed home-based records.
Please use the explanatory comment field to note whether the total reported number of
home-based records reflects a combination mother and child health book as well as TT/Td
vaccination cards, if used.
If home-based records for WCBA are not used in the country, report NR for not relevant.
Please report all institutions that are involved in the financing of home-based vaccination records for
2650 children in your country. Please utilize the explanatory comment field to provide further clarifications as #VALUE!
necessary.
Please report whether the national immunization programme / Ministry of Health or other
2660 #VALUE!
institution (please specify in the explanatory comment field) is responsible for printing
home-based vaccination records for children in your country.
2B. Procurement Source
B_2010 - Enter the year when the contract became effective for supply of each reported vaccine. Preferably, #VALUE!
B_2600 (A) data should reflect procurement that happened in the past year. In case of multi-year contracts, please
choose the year when the contract was initially signed.
B_2010 - Pick the type of presentation from the drop-down menu. If you cannot find it in the drop- #VALUE!
B_2600 (B) down menu, please enter the name of the vaccine type directly in the cell.
Pick the vaccine type from the product drop-down menu. In case the product is not included in the
B_2010 -
drop-down menu, choose the option "Other" from the drop-down list and provide your comments as #VALUE!
B_2600 (C)
appropriate in column Comments.
B_2010 - Enter the number of doses per primary container. The primary container could be a vial,
ampoule, applicator, plastic tube, prefilled syringe, etc. #VALUE!
B_2600 (D)
B_2010 - The company that made the vaccine; e.g. Serum Institute of India, Sanofi Pasteur, etc. Pick the name
of the manufacturer from the drop-down menu or enter the name of the manufacturer directly in the #VALUE!
B_2600 (E)
cell.
B_2010 - Enter the number of doses of each vaccine procured at a specific price. Use separate lines #VALUE!
B_2600 (F)
to report procured products if vaccine presentation, manufacturer or price differ.
B_2010 - Enter the name of the agency responsible for procurement in your country. If the agency in charge of
procurement is not listed in the drop down list, select Other and provide comments as appropriate in #VALUE!
B_2600 (G)
the column Comments. You can also use the comments cell to give more details on the organisation
of procurement in your country.
Pick the procurement mechanism from the drop-down menu. If there is a different
procurement mechanism in your country not listed in the drop-down menu, select other
and provide your comments as appropriate in the column Comments.
Procedures used by the vaccine procuring entity to acquire the vaccines at the specified
price.
Self-procuring mechanisms:
- Open International tender: A formal and structured invitation to international bidders to
supply clearly defined and specified goods (i.e. vaccines).
- Open Local tender: A formal and structured invitation to local bidders based in the
country to supply clearly defined and specified goods (i.e. vaccines).
- Direct contract: Direct contracting refers to procurement from a single manufacturer
B_2010 -
without competition among potential suppliers. Direct contracting can be used under #VALUE!
B_2600 (H)
framework agreements, which define the terms under which individual procurement
contracts can be made for a set period of time. Direct contracting can also be used for the
purchase of items that are not available from any other source, or in emergency
situations.
- Restricted tender: Formal tendering procedure in which only selected firms are invited
to bid.
- Request for Quotations: An informal invitation to submit a quotation for a limited
amount.
Pool procurement mechanisms:

- UNICEF Supply Division
- PAHO Revolving Fund
- Other pool procurement mechanism
B_2010 - Pick the answer from the drop down list. Single delivery means that the contract was only for a one-
#VALUE!
B_2600 (I) time delivery with no contract duration specified.
Enter the price per dose paid (in the currency indicated in the column currency)
B_2010 -
according to contractual delivery terms. In case the primary container is a multidose vial, #VALUE!
B_2600 (J)
the price should not be given for the full container but per dose. Use separate lines to
report multiple procurements of the same product if vaccine price differ.
Enter the currency used to express the vaccine price according to contractual provisions (e.g. EUR,
B_2010 - USD etc.). If payment is done in local currency with an agreed exchange rate to another currency #VALUE!
B_2600 (K) specified in the contract with the manufacturer, please indicate the exchange rate in the column
Comments.
B_2010 - Indicate if the price provided in column K includes or not the VAT. Pick the answer from
the drop down list. #VALUE!
B_2600 (L)
B_2010 - If vaccines in your country are subject to VAT, precise the percentage of the VAT that applies to this
particular vaccine. #VALUE!
B_2600 (M)
01+000WHO/UNICEF JRF data for 2016

Section Instructions, pg. 18
360754162.xls
Return
to item
The Incoterm your country was quoted for the specified price, e.g FCA, CIP, DDP, etc. The
B_2010 - Incoterms rules or International Commercial Terms are a series of pre-defined commercial
terms published by the International Chamber of Commerce (ICC). They are widely used #VALUE!
B_2600 (N)
in International commercial transactions or procurement processes to indicate what is
included in the price (insurance, freight costs, handling charges, points of delivery, etc.).
Please see the Incoterm table and calculation example annexed for further details. If the
Incoterm for a specific procurement cannot be identified, select "Unknown".
The origins of the funds used to purchase vaccines and related items. Pick the answer from the drop
B_2010 - down list. If the source of funding used in your country cannot be identified in the drop down list, select #VALUE!
B_2600 (O) Other and provide comments as appropriate in the column Comments.
Details on listed answers:
- Central government: The government pays for the vaccines out of its own budget.
- Sub-national authority: An administrative entity (e.g. regional) pays for the vaccines.
- Health insurance agency: The health insurance agency pays for the vaccines.
- Donor: Donor funds are used for the procurement of vaccines, either through direct payment by the
donor or through donor funds that are incorporated into the governments budget specifically for the
procurement of vaccines.
- Mixed: The government and donor (eg Gavi) co-finance the vaccines.
Any notes you may want to describe better the product and its procurement
characteristics (delivery information, price components, observations, additional
B_2010 - information, etc.) For example, in some countries delivery terms (incoterms) are DDP
#VALUE!
B_2600 (P) central store, while in others - it may be DDP regional stores, or DDP district stores, or
DDP service provision level. Such information is essential to understand what the vaccine
price does include.
3. School Based Immunization
Please complete the table by using one row for each vaccine and each target group. Examples: if TT
and MR is given in grade 2 and TT in grade 8, use three rows (TT-grade 2; MR-grade 2; TT-grade 8); if
3060-3170 #VALUE!
TT and MR are given to children aged 8 years, and TT to children aged 14 years, use three rows (TT-8
years; MR-8 years; TT-14 years)
"Grade / Level" indicates the class or grade that is targeted for the vaccine concerned.
Complete this cell if children in school are targeted by class or grade, regardless of their
3060-3170
age. Please use the local gradation system, or use a class grading system of 1 to 12, #VALUE!
(A)
where class 1 equals the first year in primary school, class 2 the second year of primary
school, etc.
3060-3170
#VALUE!
(B) "Age group" indicates the age groups that are targeted for the vaccine concerned. Complete this cell if
children are targeted according to their age rather than according to the class they are in.
3060-3170 "Number targeted" is the number of children targeted through the school-based
immunization for each dose. If school-based immunization is not given in all the areas of #VALUE!
(E)
the country, the target is the number of children in the areas where school-based
immunization is being implemented
3060-3170
"Number vaccinated in school": the number for children who received this dose in the areas where #VALUE!
(F) school-based immunization is being implemented.
3060-3170
"Other intervention given with the vaccine": Mention any other intervention (e.g. growth #VALUE!
(G)
monitoring, antihelmintics,) that is given at the same time as the vaccination contact
4. Coverage
Report routine immunization coverage in this table using the administrative method, that is,
using data from the registry system on the number of doses administered. Include only
doses given that are part of the national immunization schedule. Usually this means that
these doses are recorded on the recipient's immunization record. Routine immunization
may include additional immunization delivery strategies (such as Periodic Intensification
40104240 #VALUE!
of Routine Immunization) or school-based immunization. Not considered as "routine" are
doses that are given as part of "supplemental immunization activities", i.e. doses that are
given outside the immunization schedule, e.g. doses given in campaigns intended to
achieve accelerated disease control goals. Such supplemental immunization activities, as
well as vitamin A distribution should be reported in Section 8.
Column A in this table specifies the target group for some vaccines and interventions, for
example, surviving infants for DTP3. Where the table does not specify a target group,
please describe the target group in your country, for example, 6-year-old children for
MCV2.
40104240 We acknowledge that in some countries the target population may be different from the
#VALUE!
(A) ones listed in column A. (For example, the table specifies a target group of surviving
infants for yellow fever vaccine, but some countries give yellow fever vaccine to the whole
population. Similarly, the table specifies a target group of pregnant women for TT2+, but
some countries may give TT to all women of childbearing age.) However, in order to get
standardized and comparable information across countries, we request that you provide
figures related to the specific target populations designated in column A.
Some countries may use live births as the official denominator for DTP1, DTP3, Polio3, HepB3, Hib3,
and yellow fever, rather than surviving infants as specified in the table. If this is the case, simply record
the denominator used by the country in column B.
An estimate of Surviving Infants can be calculated by subtracting the number of children

who die before they reach their first birthday from the number of children born during
that year.
40104240 (B) Number of children dying during the first year of their life can be estimated by dividing #VALUE!
the number of births by 1000 times the infant mortality rate (IMR), where the infant
mortality rate is expressed as number of infant deaths per 1000 live births.
For example if there are 3064000 live births and the infant mortality rate is 110.
3064000/1000*110= 337040 infant deaths
3064000 - 337040 = 2726960 surviving infants
Formula: Live Births - (Live births / 1000 * IMR)
Provide ONLY hepatitis B vaccine doses given within 24 hours of birth. If time of birth is
unknown, please provide doses of hepatitis B vaccine given within first day of life. (For
4020 #VALUE!
example, if the infant is born on day 0, include all HepB does given on days 0 and 1.)
This indicator is NOT equivalent to HepB1
Provide ALL hepatitis B vaccine doses given at any time from birth up until hepatitis B first dose
4030 (HepB1) is due, or as per country guidance on upper age range. This indicator is NOT equivalent to #VALUE!
HepB1. Please specify the country policy on upper age limit for hepatitis B birth dose.
This refers to the third dose of polio vaccine, excluding polio 0 (zero), if such a dose is
4080 #VALUE!
included in the national schedule.
In countries using monovalent vaccine for all doses, this refers to the third dose of hepatitis B vaccine,
including the birth dose, if such a dose is included in the national schedule.
4090 In countries that are using monovalent vaccine for the birth dose and combination vaccine for the #VALUE!
subsequent doses, HepB3 will refer to the third dose of the combination vaccine in addition to the birth
dose."
Measles-containing vaccine (MCV) includes measles vaccine, measles-rubella vaccine,

4160-4180 measles-mumps-rubella vaccine, etc. Fill in the rows for both MCV and rubella vaccines #VALUE!
even if they were given in combination.
4230 (A) The number of live births can be used as a proxy for the total number of pregnant women. #VALUE!
This refers to children who are protected at birth (PAB) against neonatal tetanus by their
mother's TT status; this information is collected during the DTP1 visit - a child is deemed
4240 #VALUE!
protected if the mother has received 2 doses of TT in the last pregnancy or at-least 3
doses of TT in previous years. If the country does not calculate PAB, leave the cells blank.
Please indicate whether the total number of delayed or late vaccine doses is routinely collected and
available at the national level. Delayed or late vaccine doses are vaccine doses administered to
children older than the recommended age for receipt of vaccine dose in the national immunization
4250 schedule, or as defined nationally. Please add any necessary explanation in the comments section. #VALUE!
For countries with the first dose of measles-containing vaccine (MCV1; i.e., M1, MR1,
MMR1, MMRV1) in the national schedule earlier than 12 months (e.g., 9-11 months)
please indicate the total number of doses of M1, MR1, MMR1 or MMRV1 administered
4260 through routine services during the second year of life (i.e., from 12 to 23 months of #VALUE!
age). Do not include doses of measles-containing vaccine administered through non-
selective supplementary immunization activities, or second doses of measles-containing
vaccine (MCV2) administered through routine services.

360754162.xls
Return
to item
For countries with first dose of measles-containing vaccine in the national schedule at 12 months or
later, please indicate the total number of M1, MR1, MMR1, or MMRV1 administered late, as defined by
4270 #VALUE!
the country. The definition of late doses may vary from country to country according to reporting
practices. Do not include doses of MCV administered through SIAs, or MCV2 doses.
Administrative coverage estimates can be biased by inaccurate numerators and/or

denominators. Use this space to describe any factors limiting the accuracy of the coverage
estimates entered in the table above. Some common problems are listed here.
Numerators may be:

- underestimated because of incomplete reporting from reporting units or the exclusion
of other vaccinating sources, such as the private sector and NGOs; or
4280-4300 #VALUE!
- overestimated because of over-reporting from reporting units, for example, when other
target groups are included.
Denominators may have problems arising from:

- population movements,
- inaccurate census estimations or projections, or
- multiple sources of data.
This table collects information about the completeness of district reporting, i.e., the main
reporting system which produced the numbers in the previous table on vaccine coverage.
4310-4320 #VALUE!
The number of expected reports is equal to the number of districts multiplied by the
number of reporting periods in the year
Report the number of HPV vaccinations given to females by their age at time of
administration for each of the recommended doses of HPV vaccine. If age is unknown but
can be estimated, report for the estimated age. For example, if vaccination is offered
4330-4400 exclusively to girls in the 6th school form and most girls in the 6th school form are eleven #VALUE!
years of age, vaccinations by dose may be reported as vaccinations for girls eleven years
of age.
If a coverage survey or other surveys with immunization modules have been conducted from 2014
4420 onwards, indicate when it took place (if more than one survey took place during this time period, select #VALUE!
the latest most recent one) ?
It is important to understand that immunization coverage figures from Section 4A can be

biased or inaccurate. Hence, Section 5 gives national authorities the opportunity to
provide estimates of what the most likely true coverage is. These official estimates may
be based on data from the administrative method, from surveys, or from other sources.
This exercise is extremely important to interpret the data.
Taking into account the data provided in the previous tables as well as any other available
information on factors affecting immunization coverage figures (e.g., private or NGO
50105230 #VALUE!
sector contributions to immunization, difficulties with demographic data, and incomplete
reporting), indicate the official estimates of national immunization coverage. If the
schedule calls for a dose between 1-2 years of age, estimate coverage by 23 months;
otherwise estimate coverage among infants.
These estimates will be reproduced in global and regional reports as the officially reported
coverage figures.
Private providers may include physicians, nurses, midwives, and pharmacists who are directly involved
in the administration of vaccines; they may work full time in the private sector or they may be
employed in the public sector and work part-time in the private sector. This question refers to the
5240 provision of vaccines, regardless of who procures the vaccines. #VALUE!
In this definition, private providers excludes Social Security, NGOs, armed forces, and missionary/faith-
based as their contribution to coverage is queried separately.
6. System Indicators
This could include an official Plan of Action (POA), multi-year plan, comprehensive multi-
year plan etc.
Comprehensive multi year plan includes:
- Costing
- Routine vaccination plans
6010 #VALUE!
- Action plans for accelerated disease control
- Plans for the introduction of new vaccines
- Logistics and vaccine management
- Cold chain management
- Social mobilization and communication
Reply Yes if the national immunization programme has a clear vision and strategy for strengthening
the immunization supply chain and logistics system in the country, and has articulated this vision and
strategy into a specific multi-year improvement plan.
Otherwise, reply:
6050 No which implies that supply chain is considered an issue but there is no specific multi-year #VALUE!
improvement plan to address the challenges; or
NR which implies that supply chain is not considered an issue for the programme and therefore, a
multi-year improvement plan is not a relevant planning document needed.
ND which implies that the response to the question is not known (no data).
A National Immunization Technical Advisory Group (NITAG) is a committee of recognized

experts that provides technical advice and recommendations to the government regarding
national immunization policies and programs. NITAG is a tool that enables the
government to make evidence based immunization policies through a transparent,
systematic process. NITAGs are not regulatory, implementation or coordinating groups
6060 #VALUE!
(as such Inter-agency Coordinating Committees or National Regulatory Authorities) and
their primary function should focus on offering technical recommendations. As such Inter-
agency Coordinating Committees are NOT to be considered as NITAGs. Please note that
countries that have an ad hoc committee should mark the No option, as the question is
asking for existence of a standing committee.
Terms of reference outlines the groups purpose, serving also as a charter that outlines the groups
6070 #VALUE!
mode of functioning and code of practice for members.
In order for a NITAG to be officially approved and accepted by the government, it should
have a legislative or adminstrative basis in the form of a ministerial decree, or any other
6080 #VALUE!
appropriate mechanism. This confirms the validity of the group and inaugurates the
formal relationship between NITAG and the national government.
It should be noted that it is difficult to fully specify the minimum type of expertise required but it is very
6090-6140 important to stress the need for expertise in pediatrics, public health, infectious diseases, epidemiology #VALUE!
and immunology. NITAG may have additional expertise and that more expertise is useful.
Altough groups can have ad hoc meetings when necessary, it is recommended to have
meetings at regular intervals on predetermined dates and at least once a year. This
6150 ensures that the group remains active and recommendations remain current. And it also #VALUE!
facilitates increased attendance rates allowing members to plan the time commitment into
their schedules in advance.
An agenda for each NITAG meeting should be distributed in advance to all members. This allows to
properly prepare for the meeting. Ideally, background materials would also be distributed prior to the
6160 meetings to provide members with current research available on the topic. The distribution of this #VALUE!
material facilitates a well rounded, informed discussion during the meeting, provided the members
receive the information within sufficient time prior to the meeting.
To ensure transparency and avoid conflicts of interests as much as possible, NITAGs

should require all members to declare their interests prior to official appointment. A
conflict of interest occurs in the case of the member having a personal investment,
activity, or relationship which may affect, or appear to affect, their responsibilities of the
NITAG. A conflict of interest, whether real or perceived, can compromise the quality of the
6170 recommendations made by the group and can compromise the reputation and integrity of #VALUE!
the NITAG. It can also compromise the credibility of the group, even if it would not
influence the recommendations. Therefore, interests should be declared prior to the
individuals official appointment as a core member. The individual should only be
appointed as a member if the person is considered an independent expert so that that
their interests do not compromise the integrity of the NITAG.
WHO encourages sharing experiences between countries and their NITAGs. In order to facilitate
6180 experience sharing process, WHO would like to circulate website or webpage addresses of NITAGs to #VALUE!
others interested.
The tool is available on the NITAG Resource Center:
http://www.nitag-resource.org/media-center/document/1517-evaluation-tool-for-
6200-6210 #VALUE!
national-immunization-technical-advisory-groups-nitags
6220-6300 Please enter the coverage data that is collected through the regular administrative coverage system. #VALUE!
6310 Drop-out rate = (DTP1DTP3) x 100 / DTP1 #VALUE!
Reply Yes if there was at least one event in the reporting year where the stock-levels of the vaccine at
national level reached zero (including the recommended 3 month buffer stock). Otherwise reply No
unless either of these two situations apply:
The vaccine is not one that is included in the national immunization schedule, then select NR (not
relevant)
6320-6440 (A) #VALUE!
The vaccine is included in the national immunization schedule and the response to the question is not
known, then select ND (no data).
The explanatory comments column can be used to enter any information on the cause of the stockout,
and the number of instances this may have occurred throughout the reporting year (if for example,
there were multiple stockout events for the same vaccine over the reporting year).

360754162.xls
Return
to item
Enter the cumulative number of months the stock-out lasted for the vaccine. Selecting 1
means that the cumulative duration of stockout for the reporting year was 1 month. In
the event the stock-out lasted less than one month (for example, a few days or weeks)
then enter 0.25 for 1 week; 0.5 for 2 weeks; and so on. Rounding up the duration is
acceptable as well. Selecting 12 means that the vaccine was not available for the entire
6320-6440
reporting year. #VALUE!
(B)
Note that if the same vaccine had multiple incidents of stockouts through the year, the
cumulative duration of the stockouts needs to be reported. For instance, if the vaccine in
question had a 1 month stockout in March and another 1 month stockout in October, then
2 months of cumulative stockouts needs to be entered.
Reply Yes if there was at least one event in the reporting year where the stock-levels of the vaccine at
district level reached zero (including the recommended 1 month buffer stock). If a district is not the last
level in the vaccine supply chain where vaccines are stored in the cold chain before service delivery,
then report this situation for the relevant level: the last level in the system where vaccines are stored
before service delivery.
Otherwise reply No unless either of these two situations apply:
6320-6440 (C) #VALUE!
The vaccine is not one that is included in the national immunization schedule, then select NR (not
relevant)
The vaccine is included in the national immunization schedule and the response to the question is not
known, then select ND (no data).
Note that a district Level stockout of vaccine can occur independently of national level stockouts.
Therefore, the answer for (C) may be "Yes" even if the answer to (A) is "No".
This question is only relevant if the response to (A) and (C) is Yes. In which case, reply
6320-6440 to (D) with the answer Yes, No or ND. If the response to both (A) and (C) is not
#VALUE!
(D) Yes then the reply to (D) should be NR.
This question is only relevant if the response to (C) is Yes. In which case, reply to (E) with the answer
6320-6440 (E) #VALUE!
Yes, No or ND. If the response to (C) is No then the reply to (E) should be NR.
Please report whether there was a national-level stock-out of home-based vaccination

records for children during 2016.
If there is no data available for whether there was a stock-out of home-based records,
6450 #VALUE!
report ND for no data.
If home-based records for children are not used in the country, report NR for not
relevant.
Reply Yes if 100% of district vaccine storage points are using an electronic and computerized stock
management system for managing vaccines.
Otherwise, reply:
6460 #VALUE!
No which implies that district vaccine storage points are using a paper based system and paper
ledgers for managing vaccine stocks.
Provide the percentage of cold chain equipment at district level that are equipped with an
electronic continuous temperature monitoring device. If districts are tracking temperature
in the cold chain using a standard dial thermometer with twice daily readings recorded,
6470 #VALUE!
then the answer to this question would be 0%. A percentage above 0% would apply only
if standard dial thermometers are being replaced with a 30 day or other electronic
continuous temperature monitoring device.
Reply Yes if the national immunization programme has a dedicated staff that is focussing on supply
chain management of vaccines. An immunization supply chain manager is defined a Ministry of Health
employee working in the national immunization department who:
Is 100% dedicated to managing the entire immunization supply chain from the arrival of vaccines at
the national level to the service point
Has been formally trained in vaccine and supply chain management
6480 #VALUE!
Has the authority and resources to manage the supply chain
Otherwise, reply:
No which implies that the national immunization programme does not have a dedicated vaccine
supply chain managers but may have a cold chain or vaccine store manager at the national vaccine
store.
Please reply Yes if at national level, vaccines are stored, transported and/or managed
together with other health commodities, drugs, pharmaceutical or medicines. A Yes
reply will indicate that your country has a more integrated health supply chain system and
that vaccines are stored, transported and/or managed as part of a Central Medical Store.
6490 #VALUE!
Reply No is vaccines are managed and handled separately and have their own dedicated
cold chain system and separate vaccine store and transport system. A No reply would
indicate that your country has a vertical vaccine supply chain separate from the Central
Medical Store
Please reply Yes if there is a national policy in the country that specifically recommends against the
storage or transport of vaccines with other temperature sensitive pharmaceuticals that require cold
chain. Reply No if there is no national policy preventing vaccines from being stored, managed and
6500 transported with other temperature sensitive pharmaceuticals. Note that the answers to question 6490 #VALUE!
are unrelated to the replies to question 6500. In other words, there can be a practice of storing,
transporting and/or managing vaccines at national level with other health commodities without there
being a formal policy. The reverse can also be true.
Unlike question 6490 and 6500 that focus on the practice and policies at national level,
this question is looking at the practice of storing other temperature sensitive
pharmaceuticals with vaccines at sub-national and service delivery levels (ex: storing
6510 #VALUE!
oxytocin, insulins, serums, anti-venoms, test kitsinside the vaccine cold chain). Reply
Yes is other temperature sensitive pharmaceuticals are stored with vaccines in the
vaccine cold chain. Reply No otherwise.
Adverse events review committee is an independent committee of recognized experts that provides
technical advice and recommendations to the government regarding vaccine safety issues. The
adverse events review committee is a tool that enables the government to assess vaccine safety
issues through a transparent, systematic process. The adverse events review committees are
6530 composed of recognized national experts, independent from the immunization program and the #VALUE!
national regulatory authority, and their primary function should focus on offering technical
recommendations. Please note that countries that have an ad hoc committee should mark the No
option, as the question is asking for existence of a standing committee.
A national system must include ALL of the following:

1) written guidelines on monitoring and investigation of reported adverse events;
2) a written list of events to monitor;
6540 3) an established mechanism to communicate data for regulatory action; and #VALUE!
4) implementation of points 1, 2 and 3.
If any of the four conditions are not met, select "no".
An AEFI will be considered serious if it results in death, is life-threatening, requires in-patient

hospitalization or prolongation of existing hospitalization, results in persistent or significant
6560 disability/incapacity, or is a congenital anomaly/birth defect. Other situations, such as other important #VALUE!
medical events that may jeopardize the patient or may require intervention to prevent one of the
outcomes above, should also be considered serious after applying medical and scientific judgment.
Please indicate where the reports were sourced from, the EPI program or the National
Regulatory Authority. Select Both EPI and NRA jointly if the data from both sources
6570 #VALUE!
have been pooled together. If it is obtained from another source (such as a National
Pharmacovigilance centre or manufacturer), select other
Incineration refers to closed methods of burning at temperatures 800C.

Open burning refers to pit burning and drum burning.
6590 Burial refers to waste burial pits and encapsulation with cement or another immobilizing #VALUE!
agent, such as sand or plaster.
Other refers to any waste-disposal policy or practice that is not listed above.
Countries that have specific line items in the national budget for the purchase of vaccines
used in routine immunizations should report yes to this question. Countries that do not
6600 #VALUE!
have specific budget lines or have a general budget for health that includes vaccines
should report no to this questions.
What it includes: This figure should include expenditures made by the Government for
routine vaccines and associated injection supplies. Government includes all administrative
levels such as national and sub-national governments as well as pooled funding. Routine
vaccines include expenditures on traditional, new and under-used vaccines. Government
financing of the GAVI co-financing payments should be included. Vaccine expenditures for
Supplemental Immunization Activities (SIAs) should NOT be included. Extra-budgetary
financing from donors, out-of-pocket and informal private payments are excluded from
this indicator.
Source(s) of information: This figure should come primarily from documents providing
6610 #VALUE!
actual vaccine expenditures such as MoH, procurement entity or NIP (National
Immunization Program) budget execution reports. Government expenditures can be
corroborated using documents from other sources such as System of Health Accounts
(SHA), ad hoc routine immunization expenditure studies, Comprehensive multi-year plan
baseline estimates or execution reports, UNICEF country office or Supply Division, or
PAHO country or regional offices.
For further instructions see Guidance Note for Strengthening Country Reporting on
Immunization and Vaccine Expenditures in the Joint Reporting Form (JRF) in the link
http://www.who.int/immunization/programmes_systems/financing/data_indicators/en/

360754162.xls
Return
to item
What it includes: This figure should include expenditures for routine vaccines and
associated injection supplies from all sources of funding (including government
expenditures on vaccines as in Indicator 6610). Vaccines for SIAs are excluded. All
sources of financing refer to government, domestic and international donors and partners,
health insurance, out of pocket and formal and informal private payments.
Source (s) of information: Government sources include MoH, procurement entities,

national or social health insurance offices, and the National Immunization Program
expenditure and/or budget execution reports. Information on donor expenditures for
6620 routine vaccines can be obtained from vaccine procurement records from the GAVI #VALUE!
Secretariat, UNICEF country office or Supply Division, PAHO country or regional office,
offices of bilateral donors, offices of multilateral donors (World Bank, regional
development banks), offices of non-governmental agencies and civil society organizations.
The value of donations of routine vaccine and expenditures by foundations, private and
other agencies should also be included.
Using indicators 6610 and 6620, calculate the percentage of government expenditure on vaccines and
6630 associated injection supplies as the ratio of government vaccine expenditures (6610) divided by total #VALUE!
vaccine expenditures (6620).
What it includes: This figure should include recurrent immunization-specific expenditures

for routine immunization financed by the government. Expenditures for routine vaccines
(traditional, new, and under-utilized) and vaccine co-financing payments using
government funds, associated injection supplies, salaries and per diems of health staff
working full-time on immunization, transport specific for immunization, vehicles and cold
chain maintenance, immunization-specific training, social mobilization, monitoring and
surveillance and program management should be included. Shared health systems costs
should NOT be included in this indicator. Government expenditures include all
administrative levels such as national and sub-national governments, all fund allocated
through the national and subnational government budgets, social health insurance and
pooled financing. Extra-budgetary financing from donors, out-of-pocket and informal
6640 private payments are excluded. #VALUE!
Source(s) of information: This figure should primarily come from documents providing
actual immunization-specific expenditures such as MoH budget expenditure reports and
NIP (National Immunization Program) budget execution reports. Government
expenditures can be corroborated using documents from other sources such as System of
Health Accounts (SHA), ad hoc routine immunization expenditure studies, the baseline
year from the cMYP or execution reports, and donor agencies, such as UNICEF country
office or Supply Division and PAHO country or regional office.
What it includes: This figure should include recurrent immunization-specific expenditures

on routine immunization from all funding sources, including results from Indicator 6640.
Expenditures for routine vaccines (traditional, new, and under-utilized) and associated
injection supplies, salaries and per diems of health staff working full-time on
immunization, transport specific for immunization, vehicles and cold chain maintenance,
immunization-specific training, social mobilization, monitoring and surveillance, and
program management should be included. Shared health systems costs should NOT be
included in this indicator.
Sources of information: This figure should primarily come from documents providing
6650 actual immunization specific expenditures such as MoH and NIP (National Immunization #VALUE!
Program) budget execution reports. Other sources include Health insurance, domestic
private partners, international partner agencies and organizations. Total immunization
expenditures can be corroborated using documents from other sources such as System of
Health Accounts (SHA), ad hoc routine immunization expenditure studies, the baseline
year from the cMYP or execution reports, and donor agencies, such as UNICEF country
office or Supply Division and PAHO country or regional office.
To estimate this percentage, divide total government expenditures on routine

6660 immunization (6640) by total expenditures on routine immunization from all sources #VALUE!
(6650).
Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination
services. Vaccine hesitancy is complex and context specific varying across time, place, and vaccines. It
includes factors such as complacency, convenience, and confidence.
Vaccine hesitancy exists on a continuum between total refusal and total acceptance of all vaccines.
6740-6770 #VALUE!
Vaccine hesitancy does not apply to situations where vaccine uptake is low because of poor availability
of the vaccine (e.g. lack of vaccine due to stock outs), lack of offer of vaccination services (e.g. no
health care centres) or lack of access to vaccines (e.g. caused by natural disasters or armed crisis).
8. Supplementary activities
Record all supplementary activities related to immunization and nutritional

supplementation that were conducted at either the national or sub-national levels in
80108200 2016. These could include activities related to polio, yellow fever, measles, rubella, #VALUE!
influenza, meningitis, and tetanus toxoid vaccines; vitamin A and iron supplements;
deworming; and the distribution of insecticide treated bednets (ITNs).
Record the name of the activity (for example, NIDs, micronutrition day, child health day, or vaccination
week) and the number of the round (for example, first, second or third). If an activity involved more
80108200 (A) #VALUE!
than one vaccine or supplement, use multiple lines to describe it, placing each vaccine or supplement
on a separate line.
If children are targeted, specify the age of the target group. If women are targeted,
8010-8200
specify the age and/or pregnancy status of the target group, for example, women of #VALUE!
(D)
childbearing age or pregnant women.
Enter the official coverage estimate for the vaccine or supplement (including measles, yellow fever,
meningitis, and polio vaccines and Vitamin A). Do NOT complete for tetanus vaccine. These
80108200 (G) #VALUE!
estimates can come from a coverage survey and thus may differ from the administrative
calculation.
Record any supplementary activities related to immunization and nutritional

supplementation, at either the national or sub-national levels, that are planned for 2017
82108310 and 2018. These could include activities related to polio, yellow fever, measles, rubella, #VALUE!
influenza, meningitis, and tetanus toxoid vaccines; vitamin A and iron supplements;
deworming; and the distribution of insecticide-treated bednets (ITNs).
Indicate the name of the activity (for example, NIDs, micronutrition day, child health day or vaccination
week) and the number of the round (for example, first, second or third). If an activity involved more
82108310 (A) #VALUE!
than one vaccine or supplement, use multiple lines to describe it, entering each vaccine or supplement
on a separate line.
If children are targeted, specify the age of the target group. If women are targeted,
82108310
specify the age and/or pregnancy status of the target group, for example, women of #VALUE!
(D)
childbearing age or pregnant women.

360754162.xls
EXPLANATIONS ON INCOTERMS
The Incoterms rules or International Commercial Terms are a series of pre-defined commercial terms published by the International Chamber of
Commerce (ICC). They are widely used in International commercial transactions or procurement processes to indicate what is included in the price
(insurance, freight costs, handling charges, points of delivery, etc.).
Allocations of costs buyer/seller according to Incoterms 2010 trade terms

Carriage
(Sea Carriage
Export- Unloading Loading Freight/Air Unloading Loading to place
Customs Carriage of truck in charges Freight) to charges on truck of Import
Incoterms declaratio to port of port of in port of port of in port of in port of destinatio customs Import
2010 n export export export import import import n Insurance clearance taxes
EXW Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer
FCA Seller Seller Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer
FAS Seller Seller Seller Buyer Buyer Buyer Buyer Buyer Buyer Buyer Buyer
FOB Seller Seller Seller Seller Buyer Buyer Buyer Buyer Buyer Buyer Buyer
CFR Seller Seller Seller Seller Seller Seller Buyer Buyer Buyer Buyer Buyer
CIF Seller Seller Seller Seller Seller Seller Buyer Buyer Seller Buyer Buyer
CPT Seller Seller Seller Seller Seller Seller Seller Seller Buyer Buyer Buyer
CIP Seller Seller Seller Seller Seller Seller Seller Seller Seller Buyer Buyer
DAT Seller Seller Seller Seller Seller Seller Seller Seller Seller Buyer Buyer
DAP Seller Seller Seller Seller Seller Seller Seller Seller Seller Buyer Buyer
DDP Seller Seller Seller Seller Seller Seller Seller Seller Seller Seller Seller
Incoterms is a trademark of the International Chamber of Commerce (ICC). Formore details, please visit the ICC web site
http://www.iccwbo.org/products-and-services/trade-facilitation/incoterms-2010/the-incoterms-rules/
RULES
Ex Works FOR ANYthat
means MODE OR MODES
the seller OF TRANSPORT
delivers when it places the goods at the disposal of the buyer at the sellers premises or at another
EXW
named placeEx Works factory, warehouse, etc.). The seller does not need to load the goods on any collecting vehicle, nor does it
(i.e.,works,
need
Free to clear the
Carrier goods
means forthe
that export,
sellerwhere such
delivers theclearance is applicable.
goods to the carrier or another person nominated by the buyer at the sellers premises
or another
FCAnamed
Free Carrier
place. The parties are well advised to specify as clearly as possible the point within the named place of delivery, as
the risk passes
Carriage to the
Paid To buyer
means at the
that thatseller
point.delivers the goods to the carrier or another person nominated by the seller at an agreed place
(if any CPT Carriage
such Paid Tobetween parties) and that the seller must contract for and pay the costs of carriage necessary to bring the
place is agreed
goods to the named place of destination.
CIP Carriage And Insurance Paid To
necessary to bring the goods to the named place of destination.
insurance protection, it will need either to agree as much expressly with the seller or to make its own extra insurance arrangements.
DAT Delivered At Terminal
goods to and unloading them at the terminal at the named port or place of destination.
DAP Delivered At Place
place.
DDP Delivered Duty Paid
import, to pay any duty for both export and import and to carry out all customs formalities.

Section Incoterm, pg. 23
360754162.xls
Instructions for Section 2A
###
(Immunization Schedule)
Use the table in Section 2A to describe the 2016 national immunization schedule and any planned vaccine introductions. Complete the rows for all
vaccines and supplements currently in use in the country.
Columns A-F: Indicate the age at which each dose of a vaccine or supplement is administered using the following codes: B=Birth, D=Days,
W=Weeks, M=Months, and Y=Years. Write the number for the relevant time unit after the code so that, for example, age 6 months is written as M6.
For HPV, if the vaccine is recommended at a certain grade, please enter the most common age at the grade.
Examples:
1st A. 1st B. 2nd C. 3rd D. 4th E. 5th F. 6th 2nd A. 1st B. 2nd C. 3rd D. 4th E. 5th F. 6th
example dose dose dose dose dose dose example dose dose dose dose dose dose
First
DTP W6 W10 W14 TT contact +M1 +M6 +Y1 +Y1
pregnancy
Do not put the actual number of doses given in 2016 in these cells. That information will be collected in Table 4A.
If there are plans to introduce a vaccine that is not currently in use, enter the month and year of the planned introduction in column G-H.
For all pertussis-containing vaccines, please use the drop-down list to specify which type is used: an inactivated whole cell wP or acellular aP vaccine.
If the type of vaccine is not specified, whole cell is assumed.
For pneumococcal conjugate, Rotavirus and HPV vaccines, please specify which type is used by entering the number of valents in the space
provided.
Column I: If a vaccine or supplement is given throughout the entire country, pick "national" from the drop-down list. If it is given only in certain
regions of the country, pick "subnational". This column refers only to geographical areas and not to special target or risk groups.
Column J: If a vaccine is not given to the entire population, specify the target group (for example, adults over 65, travellers, diabetes patients, or
displaced persons).
Rows 2540-2620 provide extra lines for additional information. In Section 2A, use this space to record vaccines that are currently in use but are
not listed above.

Section Instr_Schedule, pg. 24
360754162.xls

Who Unicef JRF en

Caricato da

Informazioni sul documento

Titolo originale

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Who Unicef JRF en

Caricato da

Copyright:

Formati disponibili

Annual Report on Immunization Performance for the Period

January-December 2016 from Ministry of Health

If a question is not relevant, enter "NR" (not relevant).

Country: Date report submitted: 2017

0030 Email address

Name of UNICEF contact (Name of the UNICEF contact

0050 Email address of UNICEF contact

Name of WHO contact (Name of the WHO contact in

0070 Email address of WHO contact

Total number of districts in the country (instructions)

WHO/UNICEF JRF data for 2016000000

Reported cases for the year 2016

Laboratory Investigation C. Confirmed Cases

#VALUE! #VALUE! #VALUE!

1040 Total tetanus (all tetanus including NT)

1100 Congenital rubella syndrome

WHO/UNICEF JRF data for 2016000000

Recommended age of administration I.

2010 BCG Bacille Calmette-Gurin vaccine <pick one>

Tetanus and diphtheria toxoid with inactivated polio vaccine, children's

2110 Dip Diphtheria vaccine, children's dose <pick one>

2120 DT Tetanus and diphtheria toxoid, children's dose <pick one>

Tetanus, diphtheria toxoid, acelular perussis for older children and

Tetanus, diphtheria toxoid, acellular pertussis with inactivated polio

Tetanus, diphtheria toxoid with inactivated polio vaccine for older

2170 TT Tetanus toxoid <pick one>

2200 HepA_Adult Adult Hepatitis A vaccine <pick one>

2210 HepA_Pediatric Pediatric Hepatitis A vaccine <pick one>

2220 HepB_Adult Adult Hepatitis B vaccine <pick one>

2230 HepB_Pediatric Pediatric Hepatitis B vaccine <pick one>

2240 Hib Haemophilus influenza type b vaccine <pick one>

2250 OPV Oral polio vaccine <pick one>

2260 IPV Inactivated polio vaccine <pick one>

2270 Measles Measles vaccine <pick one>

2280 MM Measles and mumps vaccine <pick one>

2290 MR Measles and rubella vaccine <pick one>

2300 MMR Measles, mumps and rubella vaccine <pick one>

2320 Mumps Mumps vaccine <pick one>

2330 JE_LiveAtd Japanese encephalitis live attenuated vaccine <pick one>

2340 JE_Inactd Japanese encephalitis inactivated vaccine <pick one>

2350 JE_rec JE recombinant vaccine <pick one>

2360 Influenza_Adult Adult seasonal influenza vaccine <pick one>

2390 Men AC Meningococcal AC <pick one>

2400 Men ACW Meningococcal ACW <pick one>

2430 Men A Meningococcal A conjugate vaccine <pick one>

2450 Pneumo_ps Pneumococcal polysaccharide vaccine <pick one>

2460 Rubella Rubella vaccine <pick one>

2470 Typhoid Typhoid fever vaccine <pick one>

2480 Varicella Varicella vaccine <pick one>

2490 YF Yellow fever vaccine <pick one>

2520 Cholera Cholera vaccine <pick one>

2530 Vit A Vitamin A supplements <pick one>

USE THE LINES BELOW TO DESCRIBE OTHER VACCINES

2540 <pick one>

2550 <pick one>

2560 <pick one>

2570 <pick one>

2580 <pick one>

2590 <pick one>

2600 <pick one>

2610 <pick one>

2620 <pick one>

WHO/UNICEF JRF data for 2016000000